Navigation Links
Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Now Available at ReportsandReports
Date:6/28/2010

DALLAS, June 28, 2010 /PRNewswire/ -- ReportsandReports announces it will carry the Gastrointestinal Disorders Therapeutics to 2016 - High Unmet Needs Triggering Strong Growth in Crohn's Disease and Irritable Bowel Syndrome Markets Market Research Report in its store.

Browse the complete Report on: http://www.reportsandreports.com/market-reports/gastrointestinal-disorders-th erapeutics-to-2016-high-unmet-need/

GBI Research's report, "Gastrointestinal disorders therapeutics, analysis and forecasts to 2016 - high unmet needs triggering strong growth in crohn's disease and irritable bowel syndrome markets", provides in-depth analysis of the unmet needs, drivers and barriers that affect the global gastrointestinal disorder therapeutics market. It analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts. GBI Research finds that the gastrointestinal disorder therapeutics market will decline during the period 2009-2016. This decline is primarily driven by the negative growth of gastroesophageal reflux disease (GERD) therapeutics market which is attributed to loss of drug patents and entry of generics. However, other key gastrointestinal disorders such as crohn's disease and irritable bowels syndrome therapeutics market will continue to grow due to strong late stage pipeline that will address the unmet needs. The global gastrointestinal disorder therapeutics market is a highly fragmented market and big players are facing stiff competition. The forthcoming patent expiries of major drugs have increased the competition, driving the consolidation further. The increasing pressure has also driven companies to enter into licensing agreements. This allows companies to expand product portfolio and improve their competitive positions in the market.

    Scope

    - The scope of this report includes:
    - Annualized market data for the gastrointestinal disorder
      therapeutics market from 2001 to 2009, forecast forward to 2016
    - Analysis of the leading therapeutic segments. These include
      crohn's disease, ulcerative colitis, irritable bowel syndrome, and
      gastroesophageal reflux disease.
    - Analysis of the gastrointestinal disorder therapeutics market in
      the leading geographies of the world, which include the US, the UK,
      Germany, France, Italy, Spain, and Japan
    - Market characterization of the gastrointestinal disorder
      therapeutics market including market size, annual cost of therapy, and
      treatment usage patterns
    - Key drivers and barriers that have a significant impact on the
      market
    - Coverage of pipeline molecules in various phases of drug
      development
    - Competitive benchmarking of leading companies. The key companies
      studied in this report are AstraZeneca, Takeda pharmaceutical company
      Ltd., Eisai pharmaceuticals Nycomed, Pfizer Inc, GlaxoSmithKline,
      Novartis AG, and Johnson & Johnson.
    - Key M&A activities, licensing agreements, that have taken place
      between 2008 and 2009 in the global gastrointestinal disorder
      therapeutics market


    Reasons to Buy

    - The report will enhance your decision making capability. It
      will allow you to
    - Align product portfolio to the markets with high growth potential
    - Develop market-entry and market expansion strategies by
      identifying the leading therapeutic segments and geographic markets
      poised for strong growth
    - Reinforce R&D pipelines by identifying new target mechanisms
      which can produce first in class molecules with more efficiency and
      better safety
    - Develop key strategic initiatives by understanding key focus
      areas of leading companies
    - Exploit in-licensing and out-licensing opportunities by
      identifying products that could fill portfolio gaps


    Table of Contents

    1 Executive Summary 1
    2 Table of Contents 3
    2.1 List of Tables 8
    2.2 List of Figures 11
    3 Global Gastrointestinal Disorder Therapeutics Market: Scope of
    Research 13
    3.1 Introduction 13
    3.2 GBI Research Report Guidance 13
    4 Global Gastrointestinal Disorder Therapeutics Market: Market
      Characterization 14
    4.1 Market Forecasts 14
    4.2 Annual Cost of Treatment 15
    4.3 Usage Patterns 16
    4.3.1 Diseased Population 16
    4.3.2 Treatment Seeking Population 17
    4.3.3 Diagnosis Population 18
    4.3.4 Prescription Population 19
    4.3.5 Threapy Usage Patterns 20
    4.3.6 Geographical Distribution 21
    5 Global Gastrointestinal Disorder Therapeutics Market: US Market 22
    5.1 Market Overview 22
    5.2 Market Forecasts 22
    5.3 Annual Cost of Treatment 23
    5.4 Usage Patterns 24
    5.4.1 Diseased Population 24
    5.4.2 Treatment Seeking Population 25
    5.4.3 Diagnosis Population 26
    5.4.4 Prescription Population 27
    5.4.5 Threapy Usage Patterns 28
    6 Global Gastrointestinal Disorder Therapeutics Market: European
    Market 30
    6.1 Market Overview 30
    6.2 Market Forecasts 30
    6.3 Annual Cost of Treatment 31
    6.4 Usage Patterns 32
    6.4.1 Diseased Population 32
    6.4.2 Treatment Seeking Population 33
    6.4.3 Diagnosis Population 34
    6.4.4 Prescription Population 35
    6.4.5 Therapy Usage Patterns 36
    7 Global Gastrointestinal Disorder Therapeutics Market : Japan Market 38
    7.1 Market Overview 38
    7.2 Market Forecasts 38
    7.3 Annual Cost of Treatment 39
    7.4 Usage Patterns 40
    7.4.1 Diseased Population 40
    7.4.2 Treatment Seeking Population 41
    7.4.3 Diagnosis Population 42
    7.4.4 Prescription Population 43
    7.4.5 Therapy Usage Patterns 44
    8 Global Irritable Bowel Syndrome Therapeutics Market 46
    8.1 Market Overview 46
    8.2 Market Forecasts 46
    8.3 Annual Cost of Treatment 48
    8.4 Usage Patterns 49
    8.4.1 Diseased Population 49
    8.4.2 Treatment Seeking Population 50
    8.4.3 Diagnosis Population 51
    8.4.4 Prescription Population 52
    8.4.5 Threapy Usage Patterns 53
    8.5 Product Analysis 54
    8.5.1 Lotronex (Alosetron) 54
    8.5.2 Amitiza (Lubiprostone) 55
    8.5.3 Colpermin (Peppermint Oil) 55
    8.5.4 Bentyl (Dicyclomine hydrochloride) 55
    8.6 Drug Pipeline Analysis 56
    9 Global Ulcerative Colitis Therapeutics Market 57
    9.1 Market Overview 57
    9.2 Market Forecasts 57
    9.3 Annual Cost of Treatment 59
    9.4 Usage Patterns 60
    9.4.1 Diseased Population 60
    9.4.2 Treatment Seeking Population 61
    9.4.3 Diagnosis Population 62
    9.4.4 Prescription Population 63
    9.4.5 Threapy Usage Patterns 65
    9.5 Product Analysis 66
    9.5.1 Asacol 66
    9.5.2 Lialda 66
    9.5.3 Pentasa 66
    9.5.4 Apriso 67
    9.5.5 Colazal 67
    9.5.6 Remicade 67
    9.5.7 Azulfidine 67
    9.6 Drug Pipeline Analysis 68
    10 Global GERD Therapeutics Market 69
    10.1 Market Overview 69
    10.2 Market Forecasts 69
    10.3 Annual Cost of Treatment 71
    10.4 Usage Patterns 72
    10.4.1 Diseased Population 72
    10.4.2 Treatment Seeking Population 73
    10.4.3 Diagnosis Population 74
    10.4.4 Prescription Population 75
    10.4.5 Threapy Usage Patterns 76
    10.5 Product Analysis 77
    10.5.1 Nexium (esomeprazole) 77
    10.5.2 Aciphex (rabeprazole sodium) 77
    10.5.3 Prevacid (lansoprazole) 77
    10.5.4 Prilosec (omeprazole) 78
    10.5.5 Protonix (pantoprazole sodium) 78
    10.5.6 Tagamet (cimetidine) 78
    10.5.7 Pepcid (famotidine) 78
    10.5.8 Zantac (ranitidine hydrochloride) 78
    10.5.9 Axid (nizatidine) 78
    10.6 Drug Pipeline Analysis 79
    11 Global Crohn's Disease Therapeutics Market 80
    11.1 Market Overview 80
    11.2 Market Forecasts 81
    11.3 Annual Cost of Treatment 82
    11.4 Usage Patterns 83
    11.4.1 Diseased Population 83
    11.4.2 Treatment Seeking Population 84
    11.4.3 Diagnosis Population 86
    11.4.4 Prescription Population 87
    11.4.5 Therapy Usage Patterns 88
    11.5 Product Analysis 89
    11.5.1 Entocort EC (budenoside) 90
    11.5.2 Humira (adalimumab) 90
    11.5.3 Tysabri (natalizumab) 90
    11.5.4 Remicade (infliximab) 90
    11.5.5 Cimzia (cetrolizumab pegol) 91
    11.6 Drug Pipeline Analysis 91
    12 Global Gastrointestinal Disorder Therapeutics Market: Market Drivers
    and Restraints 92
    12.1 Market Drivers 92
    12.1.1 Steady Increase in the Elderly Population 93
    12.1.2 Stable Increase in Incidence Rates for Gastrointestinal
    Disorders 93
    12.1.3 Increase in Awareness Levels of Disease Progression and
    Etiology 93
    12.2 Market Restraints 93
    12.2.1 Entry of Generics Pose a Serious Problem for Primary
    Manufacturers 94
    12.2.2 Presence of Serious Side Effects for Certain Classes of
    Therapeutic Drugs 94
    13 Global Gastrointestinal Disorder Therapeutics Market : Key Market
    Trends 95
    14 Global Gastrointestinal Disorder Therapeutics Market: Competitive
    Landscape 96
    14.1 Overview 96
    14.2 Competitive Profiling 96
    14.3 GlaxoSmithKline, Inc 96
    14.3.1 Overview 96
    14.3.2 Business Description 96
    14.4 AstraZeneca 97
    14.4.1 Company Overview 97
    14.4.2 AZD3355 98
    14.5 Pfizer Incorporated 99
    14.5.1 Overview 99
    14.5.2 Business Description 99
    14.6 Novartis Ag 100
    14.6.1 Company Overview 100
    14.6.2 Business Description 100
    14.7 ChemoCentryx Inc. 101
    14.7.1 Overview 101
    14.7.2 Gastrointestinal Disease Portfolio 101
    14.7.3 Crohn's Disease Product Portfolio 101
    14.8 Bristol-Myers Squibb 102
    14.8.1 Overview 102
    14.8.2 Gastrointestinal Disease Portfolio 102
    14.8.3 Crohn's Disease Product Portfolio 102
    14.9 Abbott Laboratories 103
    14.9.1 Overview 103
    14.9.2 Gastrointestinal Disease Portfolio 103
    14.9.3 Crohn's Disease Product Portfolio 103
    14.10 XenoPort, Inc. 104
    14.10.1 Company Overview 104
    14.10.2 XP19986 104
    14.11 Addex Pharmaceuticals 105
    14.11.1 Company Overview 105
    14.11.2 ADX10059 105
    14.12 Vecta Ltd. (Vecta) 106
    14.12.1 Company Overview 106
    14.12.2 Vecam 106
    14.13 Ironwood Pharmaceuticals and Forest Laboratories 107
    14.13.1 Company Overview 107
    14.13.2 IBS pipeline portfolio 108
    14.14 Tioga Pharmaceuticals 109
    14.14.1 Company Overview 109
    14.14.2 IBS Pipeline Porfolio 109
    14.15 Alimentary Health Ltd & P & G 111
    14.15.1 Company Overview 111
    14.15.2 IBS Pipeline Portfolio 111
    14.15.3 Bifantis (Bifidobacterium infantis 35624) 111
    14.16 Lexicon 112
    14.16.1 Company Overview 112
    14.16.2 IBS pipeline portfolio 112
    14.16.3 LX-103 112
    14.17 Salix Pharmaceuticals 113
    14.17.1 Overview 113
    14.17.2 Business Description 113
    14.17.3 IBS pipeline portfolio 114
    Xifaxan (Rifaximin) 114
    14.17.4 Ulcerative Colitis pipeline portfolio 115
    14.18 Astellas Pharma 115
    14.18.1 Overview 115
    14.18.2 IBS Pipeline Portfolio 115
    15 Gastrointestinal Disorder Therapeutics Market: Pipeline Analysis 118
    15.1 Preclinical 119
    15.2 Phase I 120
    15.3 Pipeline II 122
    15.4 Phase III 126
    15.5 Promising Drugs under Clinical Development for Crohn's Disease 129
    15.5.1 Myoconda 129
    15.5.2 Traficet-EN (CCX282) 129
    15.5.3 MLN0002 (vedolizumab) 129
    15.5.4 Orencia (abatacept) 129
    15.5.5 ABT-874 129
    15.5.6 Stelara 129
    15.6 Promising Drugs under Clinical Development for Irritable Bowel
    Syndrome 130
    15.6.1 Linaclotide (Linaclotide Acetate) 130
    15.6.2 Asimadoline 130
    15.6.3 Xifaxan (Rifaximin) 130
    15.6.4 Bifantis (Bifidobacterium infantis 35624) 130
    15.6.5 LX-103 131
    15.6.6 YM060 (Ramosetron hydrochloride) 131
    15.7 Promising Drugs under Clinical Development for GERD 131
    15.7.1 XP19986 131
    15.7.2 AZD3355 131
    15.7.3 ADX10059 132
    15.7.4 Vecam 132
    15.8 Promising Drugs under Clinical Development for Ulcerative
    Colitis 132
    15.8.1 Prograf (Tacrolimus) 132
    15.8.2 Vedolizumab 132
    15.8.3 Abatacept 132
    15.8.4 Adalimumab 133
    15.8.5 Golimumab 133
    16 Global Gastrointestinal Disorder Therapeutics Market: Strategic
    Consolidations 134
    16.1 Mergers and Acquisitions 134
    16.1.1 Overview 134
    16.1.2 GlaxoSmithKline Acquires AZ Tika Of AstraZeneca 134
    16.1.3 ViroPharma Acquires Lev Pharmaceuticals 134
    16.1.4 UCB Acquires Remaining Stake In Schwarz Pharma 134
    16.1.5 Teva Pharmaceutical Acquires Bentley Pharmaceuticals 134
    16.1.6 Gilead Sciences Acquires Nycomed Limited 135
    16.2 Licensing Agreements 135
    16.2.1 Overview 135
    17 Global Gastrointestinal Disorder Therapeutics Market : Appendix 138
    17.1 Market Definitions 138
    17.2 Abbreviations 138
    17.3 Research Methodology 139
    17.3.1 Coverage 139
    17.3.2 Secondary Research 139
    17.3.3 Primary Research 140
    17.3.4 Forecasts 140
    17.3.5 Expert Panel Validation 142
    17.4 Contact Us 143
    17.5 Disclaimer 143


    2.1 List of Tables

Table 1: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2001-2009 14

Table 2: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2009-2016 14

Table 3: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment, 2001-2009 15

Table 4: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment, 2009-2016 15

Table 5: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population, 2001-2009 16

Table 6: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population, 2009-2016 16

Table 7: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 17

Table 8: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 17

Table 9: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosis Population, 2001-2009 18

Table 10: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosis Population, 2009-2016 18

Table 11: Gastrointestinal Disorder Therapeutics Market, Global, Prescription Population, 2001-2009 19

Table 12: Gastrointestinal Disorder Therapeutics Market, Global, Prescription Population, 2009-2016 19

Table 13: Gastrointestinal Disorder Therapeutics Market, Global, Usage Patterns, 2001-2009 20

Table 14: Gastrointestinal Disorder Therapeutics Market, Global, Usage Patterns, 2009-2016 21

Table 15: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2001-2009 22

Table 16: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2009-2016 22

Table 17: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment , 2001-2009 23

Table 18: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment, 2009-2016 23

Table 19: Gastrointestinal Disorder Therapeutics Market, The US, Diseased Population, 2001-2009 24

Table 20: Gastrointestinal Disorder Therapeutics Market, The US, Diseased Population, 2009-2016 24

Table 21: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Seeking Population, 2001-2009 25

Table 22: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Seeking Population, 2009-2016 25

Table 23: Gastrointestinal Disorder Therapeutics Market, The US, Diagnosis Population, 2001-2009 26

Table 24: Gastrointestinal Disorder Therapeutics Market, The US, Diagnosis Population, 2009-2016 26

Table 25: Gastrointestinal Disorder Therapeutics Market, The US, Prescription Population, 2001-2009 27

Table 26: Gastrointestinal Disorder Therapeutics Market, The US, Prescription Population, 2009-2016 27

Table 27: Gastrointestinal Disorder Therapeutics Market, The US, Usage Patterns, 2001-2009 28

Table 28: Gastrointestinal Disorder Therapeutics Market, The US, Usage Patterns, 2009-2016 29

Table 29: Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($bn), 2001-2009 30

Table 30: Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($bn), 2009-2016 30

Table 31: Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of Treatment, 2001-2009 31

Table 32: Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of Treatment, 2009-2016 31

Table 33: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased Population, 2001-2009 32

Table 34: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased Population, 2009-2016 32

Table 35: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking Population, 2001-2009 33

Table 36: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking Population, 2009-2016 33

Table 37: Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population, 2001-2009 34

Table 38: Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population, 2009-2016 34

Table 39: Gastrointestinal Disorder Therapeutics Market, Europe, Prescription Population, 2001-2009 35

Table 40: Gastrointestinal Disorder Therapeutics Market, Europe, Prescription Population, 2009-2016 35

Table 41: Gastrointestinal Disorder Therapeutics Market, Europe, Usage Patterns, 2001-2009 36

Table 42: Gastrointestinal Disorder Therapeutics Market, Europe, Usage Patterns, 2009-2016 37

Table 43: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2001-2009 38

Table 44: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2009-2016 38

Table 45: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment , 2001-2009 39

Table 46: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment, 2009-2016 39

Table 47: Gastrointestinal Disorder Therapeutics Market, Japan, Diseased Population, 2001-2009 40

Table 48: Gastrointestinal Disorder Therapeutics Market, Japan, Diseased Population, 2009-2016 40

Table 49: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Seeking Population, 2001-2009 41

Table 50: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Seeking Population, 2009-2016 41

Table 51: Gastrointestinal Disorder Therapeutics Market, Japan, Diagnosis Population, 2001-2009 42

Table 52: Gastrointestinal Disorder Therapeutics Market, Japan, Diagnosis Population, 2009-2016 42

Table 53: Gastrointestinal Disorder Therapeutics Market, Japan, Prescription Population, 2009-2016 43

Table 54: Gastrointestinal Disorder Therapeutics Market, Japan, Prescription Population, 2001-2009 43

Table 55: Gastrointestinal Disorder Therapeutics Market, Japan, Usage Patterns, 2001-2009 44

Table 56: Gastrointestinal Disorder Therapeutics Market, Japan, Usage Patterns, 2009-2016 45

Table 57: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2001-2009 47

Table 58: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2009-2016 47

Table 59: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment, 2001-2009 48

Table 60: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment, 2009-2016 48

Table 61: Irritable Bowel Syndrome Therapeutics Market, Global, Diseased Population, 2001-2009 49

Table 62: Irritable Bowel Syndrome Therapeutics Market, Global, Diseased Population, 2009-2016 49

Table 63: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 50

Table 64: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 50

Table 65: Irritable Bowel Syndrome Therapeutics Market, Global, Diagnosis Population, 2001-2009 51

Table 66: Irritable Bowel Syndrome Therapeutics Market, Global, Diagnosis Population, 2009-2016 51

Table 67: Irritable Bowel Syndrome Therapeutics Market, Global, Prescription Population, 2001-2009 52

Table 68: Irritable Bowel Syndrome Therapeutics Market, Global, Prescription Population, 2009-2016 52

Table 69: Irritable Bowel Syndrome Therapeutics Market, Global, Usage Patterns, 2001-2009 53

Table 70: Irritable Bowel Syndrome Therapeutics Market, Global, Usage Patterns, 2009-2016 54

Table 71: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2001-2009 58

Table 72: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2009-2016 58

Table 73: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment , 2001-2009 59

Table 74: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment , 2009-2016 59

Table 75: Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2001-2009 60

Table 76: Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2009-2016 60

Table 77: Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 61

Table 78: Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 61

Table 79: Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2001-2009 62

Table 80: Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2009-2016 62

Table 81: Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2001-2009 64

Table 82: Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2009-2016 64

Table 83: Ulcerative Colitis Therapeutics Market, Global, Usage Patterns, 2001-2009 65

Table 84: Ulcerative Colitis Therapeutics Market, Global, Usage Patterns, 2009-2016 66

Table 85: GERD Therapeutics Market, Global, Revenue ($m), 2001-2009 70

Table 86: GERD Therapeutics Market, Global, Revenue ($m), 2009-2016 70

Table 87: GERD Therapeutics Market, Global, Annual Cost of Treatment, 2001-2009 71

Table 88: GERD Therapeutics Market, Global, Annual Cost of Treatment, 2009-2016 71

Table 89: GERD Therapeutics Market, Global, Diseased Population, 2001-2009 72

Table 90: GERD Therapeutics Market, Global, Diseased Population, 2009-2016 72

Table 91: GERD Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 73

Table 92: GERD Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 73

Table 93: GERD Therapeutics Market, Global, Diagnosis Population, 2001-2009 74

Table 94: GERD Therapeutics Market, Global, Diagnosis Population, 2009-2016 74

Table 95: GERD Therapeutics Market, Global, Prescription Population, 2001-2009 75

Table 96: GERD Therapeutics Market, Global, Prescription Population, 2009-2016 75

Table 97: GERD Therapeutics Market, Global, Usage Patterns, 2001-2009 76

Table 98: GERD Therapeutics Market, Global, Usage Patterns, 2009-2016 77

Table 99: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2001-2009 81

Table 100: Crohn's Disease Therapeutics Market, Global, Revenue ($m), 2009-2016 81

Table 101:Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment, 2001-2009 82

Table 102:Crohn's Disease Therapeutics Market, Global, Annual Cost of Treatment, 2009-2016 82

Table 103: Crohn's Disease Therapeutics Market, Global, Diseased Population, 2001-2009 83

Table 104: Crohn's Disease Therapeutics Market, Global, Diseased Population, 2009-2016 83

Table 105: Crohn's Disease Therapeutics Market, Global, Treatment Seeking Population, 2001-2009 85

Table 106:Crohn's Disease Therapeutics Market, Global, Treatment Seeking Population, 2009-2016 85

Table 107:Crohn's Disease Therapeutics Market, Global, Diagnosis Population, 2001-2009 86

Table 108:Crohn's Disease Therapeutics Market, Global, Diagnosis Population, 2009-2016 86

Table 109:Crohn's Disease Therapeutics Market, Global, Prescription Population, 2001-2009 87

Table 110:Crohn's Disease Therapeutics Market, Global, Prescription Population, 2009-2016 87

Table 111:Crohn's Disease Therapeutics Market, Global, Usage Patterns, 2001-2009 89

Table 112:Crohn's Disease Therapeutics Market, Global, Usage Patterns, 2009-2016 89

Table 113: Gastrointestinal Disorder Therapeutics Market, Global, Market Drivers, 2009 92

Table 114: Gastrointestinal Disorder Therapeutics Market, Global, Market Restraints, 2009 93

Table 115: GlaxoSmithKline - Ulcerative Colitis Pipeline, 2009 97

Table 116: Pfizer - Ulcerative Colitis Pipeline, 2009 100

Table 117: ChemoCentryx Inc. - Autoimmune and Gastrointestinal Disease Pipeline Products, 2009 101

Table 118: Bristol-Myers Squibb - Gastrointestinal Pipeline Products, 2009 102

Table 119: Abbott Laboratories - Gastrointestinal Marketed Products, 2009 103

Table 120: Abbott Laboratories - Gastrointestinal Pipeline Products, 2009 103

    Table 121: Ironwood Pharmaceuticals- IBS pipeline products, 2010 108
    Table 122: Tioga Pharmaceuticals - IBS Pipeline Products, 2010 109
    Table 123: Alimentary Health Ltd & P & G - IBS pipeline products, 2010 111
    Table 124: Lexicon - IBS pipeline portfolio, 2010 112
    Table 125: Salix Pharmaceutical - IBS Pipeline Portfolio, 2010 114
    Table 126: Salix Pharmaceuticals - Ulcerative Colitis Pipeline, 2009 115
    Table 127: Astellas Pharma - IBS Pipeline Portfolio, 2010 115

Table 128:Gastrointestinal Disorder Therapeutics Market, Global, Preclinical Pipeline, 2009 119

Table 129:Gastrointestinal Disorder Therapeutics Market, Global, Phase I Pipeline, 2009 120

Table 130:Gastrointestinal Disorder Therapeutics Market, Global, Phase II Pipeline, 2009 122

Table 131:Gastrointestinal Disorder Therapeutics Market, Global, Phase III Pipeline, 2009 126

2.2 List of Figures

Figure 1: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline by Phase (%), 2009 1

Figure 2: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements Split by Phase (%), 1998-2010 2

Figure 3: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($m), 2001-2016 14

Figure 4: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016 15

Figure 5: Gastrointestinal Disorder Therapeutics Market, Global, Diseased Population, 2001-2016 16

Figure 6: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 17

Figure 7: Gastrointestinal Disorder Therapeutics Market, Global, Diagnosis Population, 2001-2016 18

Figure 8: Gastrointestinal Disorder Therapeutics Market, Global, Prescription Population, 2001-2016 19

Figure 9: Gastrointestinal Disorder Therapeutics Market, Global, Usage Patterns, 2001-2016 20

Figure 10: Gastrointestinal Disorder Therapeutics Market, Global, Geographical Distribution of Revenues ($bn), 2001-2016 21

Figure 11: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($m), 2001-2016 22

Figure 12: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment, 2001-2016 23

Figure 13: Gastrointestinal Disorder Therapeutics Market, The US, Diseased Population, 2001-2016 24

Figure 14: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Seeking Population, 2001-2016 25

Figure 15: Gastrointestinal Disorder Therapeutics Market, The US, Diagnosis Population, 2001-2016 26

Figure 16: Gastrointestinal Disorder Therapeutics Market, The US, Prescription Population, 2001-2016 27

Figure 17: Gastrointestinal Disorder Therapeutics Market, The US, Usage Patterns, 2001-2016 28

Figure 18: Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($m), 2001-2016 30

Figure 19: Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of Treatment, 2001-2016 31

Figure 20: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased Population, 2001-2016 32

Figure 21: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking Population, 2001-2016 33

Figure 22: Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population, 2001-2016 34

Figure 23: Gastrointestinal Disorder Therapeutics Market, Europe, Prescription Population, 2001-2016 35

Figure 24: Gastrointestinal Disorder Therapeutics Market, Europe, Usage Patterns, 2001-2016 36

Figure 25: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2001-2016 38

Figure 26: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment, 2001-2016 39

Figure 27: Gastrointestinal Disorder Therapeutics Market, Japan, Diseased Population, 2001-2016 40

Figure 28: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Seeking Population, 2001-2016 41

Figure 29: Gastrointestinal Disorder Therapeutics Market, Japan, Diagnosis Population, 2001-2016 42

Figure 30: Gastrointestinal Disorder Therapeutics Market, Japan, Prescription Population, 2001-2016 43

Figure 31: Gastrointestinal Disorder Therapeutics Market, Japan, Usage Patterns, 2001-2016 44

Figure 32: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2001-2016 47

Figure 33: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016 48

Figure 34: Irritable Bowel Syndrome Therapeutics Market, Global, Diseased Population, 2001-2016 49

Figure 35: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 50

Figure 36: Irritable Bowel Syndrome Therapeutics Market, Global, Diagnosis Population, 2001-2016 51

Figure 37: Irritable Bowel Syndrome Therapeutics Market, Global, Prescription Population, 2001-2016 52

Figure 38: Irritable Bowel Syndrome Therapeutics Market, Global, Usage Patterns, 2001-2016 53

Figure 39: Irritable Bowel Syndrome Therapeutics Market, Global, Pipeline by Phases, 2009 56

Figure 40: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2001-2016 58

Figure 41: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016 59

Figure 42: Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2001-2016 60

Figure 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 61

Figure 44: Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2001-2016 62

Figure 45: Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2001-2016 63

Figure 46: Ulcerative Colitis Therapeutics Market, Global, Usage Patterns, 2001-2016 65

Figure 47: Ulcerative Colitis Therapeutics Market, Global, Pipeline by Phases, 2009 68

Figure 48: GERD Therapeutics Market, Global, Revenue ($m), 2001-2016 70

Figure 49: GERD Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016 71

Figure 50: GERD Therapeutics Market, Global, Diseased Population, 2001-2016 72

Figure 51: GERD Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 73

Figure 52: GERD Therapeutics Market, Global, Diagnosis Population, 2001-2016 74

Figure 53: GERD Therapeutics Market, Global, Prescription Population, 2001-2016 75

Figure 54: GERD Therapeutics Market, Global, Usage Patterns, 2001-2016 76

Figure 55: GERD Therapeutics Market, Global, Pipeline by Phases, 2009 79

Figure 56: Crohn's's Disease Therapeutics Market, Global, Revenue ($m), 2001-2016 81

Figure 57: Crohn's's Disease Therapeutics Market, Global, Annual Cost of Treatment, 2001-2016 82

Figure 58: Crohn's's Disease Therapeutics Market, Global, Diseased Population, 2001-2016 83

Figure 59: Crohn's's Disease Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 84

Figure 60: Crohn's's Disease Therapeutics Market, Global, Diagnosis Population, 2001-2016 86

Figure 61: Crohn's's Disease Therapeutics Market, Global, Prescription Population, 2001-2016 87

Figure 62: Crohn's's Disease Therapeutics Market, Global, Usage Patterns, 2001-2016 88

Figure 63: Crohn's Disease Therapeutics Market, Global, Usage Patterns, 2009-2016 91

Figure 64: Gastrointestinal Disorder Therapeutics Market, Global, Market Indicators, 2009 92

Figure 65: Gastrointestinal Disorder Therapeutics Market, Global, Key Market Events, 2009-2015 95

Figure 66: Gastrointestinal Disorder Therapeutics Market, Global, Key Market Events, 2009-2016 117

Figure 67: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline by Phase, 2009 118

Figure 68: Gastrointestinal Disorder Therapeutics Market, Global, Pipeline by Indication, 2009 118

Figure 69: Gastrointestinal Disorder Therapeutics Market, Global, Preclinical Pipeline by Indication, 2009 120

Figure 70: Gastrointestinal Disorder Therapeutics Market, Global, Phase I Pipeline by Indication, 2009 122

Figure 71: Gastrointestinal Disorder Therapeutics Market, Global, Phase II Pipeline by Indication, 2009 126

Figure 72: Gastrointestinal Disorder Therapeutics Market, Global, Phase III Pipeline by Indication, 2009 128

Figure 73: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements Split by Phases, 1998-2010 135

Figure 74: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements Split by Indication, 1998-2010 136

Figure 75: Gastrointestinal Disorder Therapeutics Market, Global, Licensing Agreements Split by Approved Date, 1998 - 2010 137

    Figure 76: GBI Research Methodology, 2010 139
    Figure 77: GBI Research Market Forecasting Methodology, 2010 142
    Companies mentioned

    GlaxoSmithKline, Inc
    AstraZeneca
    Pfizer Incorporated
    Novartis Ag
    ChemoCentryx Inc.
    Bristol-Myers Squibb
    Abbott Laboratories
    XenoPort, Inc.
    Addex Pharmaceuticals
    Vecta Ltd. (Vecta)
    Ironwood Pharmaceuticals and Forest Laboratories
    Tioga Pharmaceuticals
    Alimentary Health Ltd & P & G
    Lexicon
    Salix Pharmaceuticals
    Astellas Pharma


    Browse all Pharmaceuticals Reports at
http://www.reportsandreports.com/market-research/pharmaceuticals/
    Browse all GBI Research Reports at
http://www.reportsandreports.com/Publishers/gbi-research/

Related Reports

Irritable Bowel Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016 ( http://www.reportsandreports.com/market-reports/irritable-bowel-syndrome-drug -pipeline-analysis-and-market-fore/)

Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma ( http://www.reportsandreports.com/market-reports/ribonucleic-acid-rna-therapeu tics-strong-potential-to-address/)

Digestive System Irritable Bowel Syndrome Therapy Area Pipeline Report (http://www.reportsandreports.com/market-reports/digestive-system-irritable-b owel-syndrome-therapy-area-pipeline-r/)

Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016 (http://www.reportsandreports.com/market-reports/parkinsons-disease-pipeline- assessment-and-market-forecasts-to/)

Stakeholder Opinions: Cancer Cachexia - Higher profile needed to unlock market potential of neglected syndrome ( http://www.reportsandreports.com/market-reports/stakeholder-opinions-cancer-c achexia-higher-profile-needed-to-/)

Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs ( http://www.reportsandreports.com/market-reports/stakeholder-opinions-pancreat ic-cancer-gemzar-dominance-will-c/)

Pipeline and Commercial Insight: Hepatitis C - High unmet need drives rapid innovation ( http://www.reportsandreports.com/market-reports/pipeline-and-commercial-insig ht-hepatitis-c-high-unmet-need-dr/)

Pipeline Insight: Prostate Cancer Molecular targeted therapies will fulfill unmet needs in castration-resistant disease ( http://www.reportsandreports.com/market-reports/pipeline-insight-prostate-can cer-molecular-targeted-therapies-w/)

Forecast Insight: Inflammatory Bowel Disease - New product launches sustain long-term market growth ( http://www.reportsandreports.com/market-reports/forecast-insight-inflammatory -bowel-disease-new-product-launch/)

Crohn's Disease - Drug Pipeline Analysis and Market Forecasts to 2015 (http://www.reportsandreports.com/market-reports/crohns-disease-drug-pipeline -analysis-and-market-forecasts-to-/)

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

    Contact:

    Ms. Sunita
    7557 Rambler road,
    Suite 727, Dallas, TX 75231
    Tel: +1-888-989-8004
    http://www.reportsandreports.com/
    http://reportsnreports.wordpress.com/
    http://reportsandreports.blogspot.com/


'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , Feb. 9, 2016 ... Inhibitors-Pipeline Insights, 2016", report provides in depth ... development activities around the Protein-Tyrosine Phosphatase 1B ... product profiles in various stages of development ... II, Phase III and Preregistration. Report covers ...
(Date:2/8/2016)... February 8, 2016 ... Limited, an innovation-driven oncology company developing next generation ... toxic, today announced that chairman emeritus of Tata ... in the company as part of the first ... existing investors Navam Capital and Aarin Capital. ...
(Date:2/8/2016)... ... February 08, 2016 , ... Information Management Services ( ... The upgrade represents a completely new technical foundation and is so significant it ... responsive design interface, significantly increased speed for search results, a streamlined layout and a ...
(Date:2/8/2016)... program for the development of future natural products for crop ... and development center in Israel and ... Stockton has a variety of products adapted to ... in more than 35 counties worldwide. ... product Timorex Gold ® is used to control a ...
Breaking Biology Technology:
(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
(Date:1/20/2016)... , Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced sampling of S1423, its ... wearables and small screen applications including smartwatches, fitness ... Supporting round and rectangular shapes, as well as ... performance with moisture on screen, while wearing gloves, ...
(Date:1/15/2016)... 2016 Recent publicized breaches in cyber security ... ways to ensure data security and user authentication in ... Android that ties a user,s mobile number ... a hardware authorization token. Customer service agents who employ ... their KodeKey enabled device to verify their identity.  Companies ...
Breaking Biology News(10 mins):